Integrated Filing- Financial

BAFNA Pharmaceuticals has announced a board meeting to discuss the integrated financial results for the quarter and nine months ended December 31, 2024. The company reported revenue from operations of ₹33.18 crore and a total income of ₹33.38 crore.

However, the company faced a profit of ₹0.95 crore, a significant decline compared to the previous period.

The current financial performance reflects challenges in operational efficiency and increased expenses, casting a cautious outlook for investors.

The company is taking initiatives to enhance compliance with minimum public shareholding requirements, which could stabilize investor sentiment in the long run.